SUPN supernus.com: Nilai perusahaan marang volume dodolan

The Enterprise Value-to-Revenue multiple on the GURU.Markets daily chart reflects stable demand for neurological drugs, and 2717.05 indicates the current level of the metric for Supernus Pharmaceuticals (SUPN). Growth is based on eco-friendly drug production and social responsibility. The defensive qualities of the business ensure resilience to crises, as ADHD and epilepsy therapies do not depend on GDP dynamics.
SUPN (Supernus Corp): rincian analitis lan laporan miturut indikator

The EV/Sales ratio trend reflects the market value of Supernus Pharmaceuticals (SUPN) inclusive of debt relative to its annual turnover, highlighting the efficiency of its outsourced manufacturing model. This metric compares the total enterprise value to revenue, allowing investors to assess the premium for R&D potential amid minimal capital expenditures, where a sharp decline in the indicator could signal falling drug margins.